INO-5401

BIOLOGICAL3 trials

Sponsors

Inovio Pharmaceuticals, Abramson Cancer Center at Penn Medicine

Conditions

BRCA1/2 MutationGlioblastomaUrothelial Carcinoma

Phase 1

INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Active, not recruitingNCT03491683

Inovio PharmaceuticalsGlioblastoma

Start: 2018-05-31End: 2026-12-31Updated: 2026-03-19

INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma

CompletedNCT03502785

Inovio PharmaceuticalsUrothelial Carcinoma

Start: 2018-05-24End: 2025-05-09Updated: 2025-07-10

INO 5401 Vaccination in BRCA1/2 Mutation Carriers

Active, not recruitingNCT04367675

Abramson Cancer Center at Penn MedicineBRCA1/2 Mutation

Start: 2021-04-20End: 2027-03-01Target: 44Updated: 2026-02-23

Related Papers

Phase Ib study of a plasmid DNA–based immunotherapy encoding the hTERT, PSMA, and WT1 (INO-5401) +/- IL12 (INO-9012) followed by electroporation in cancer patients and healthy individuals with <i>BRCA1/2</i> mutations.

Journal of Clinical Oncology2025-05-281 citations

Intramuscular (IM) INO-5401 + INO-9012 with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma.

Journal of Clinical Oncology2022-06-0123 citations

Multicenter, Open-Label, Phase I Study of DSP-7888 Dosing Emulsion in Patients with Advanced Malignancies

Targeted Oncology2021-05-0329 citations

LTBK-01. INO-5401 AND INO-9012 DELIVERED INTRAMUSCULARLY (IM) WITH ELECTROPORATION (EP) IN COMBINATION WITH CEMIPLIMAB (REGN2810) IN NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2020-11-017 citations

INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.

Journal of Clinical Oncology2020-05-2020 citations

P858 An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab in subjects with newly-diagnosed glioblastoma (GBM)

Poster presentations2020-04-013 citations

Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)

Cancer Research2019-07-017 citations

Abstract CT114: INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)

Clinical Trials2019-07-013 citations

Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma

Cancer Research2019-07-011 citations

Abstract CT177: INO-5401 + INO-9012 in combination with atezolizumab for locally advanced unresectable or metastatic/recurrent urothelial carcinoma

Clinical Trials2019-07-01